Documented concern based on cited evidence — not a personalized safety check, not medical advice, and not a decision to combine or avoid. That decision belongs with your prescriber.

Documented concern — monitor and disclose

Clinically relevant documented concern. Disclose the supplement to your clinician and keep monitoring in place.

Mechanism and evidence

GLP-1 agonists slow gastric emptying, which can lower and delay the peak of pill hormones. For semaglutide the dedicated interaction study found bioequivalence held; for tirzepatide a single-dose study found hormone peaks roughly halved and the label added four-week barrier windows after each dose step. One class, two intensities.

Evidence tier: pk-study

The tier names the strongest cited study design. Some anchors studied the supplement on its own, or a related drug in the same class — in those pairs the grade rests on that evidence plus established pharmacology, as agreed with our medical reviewer.

What to discuss with your prescriber

  • On tirzepatide (Mounjaro, Zepbound) with a pill: the label advises a non-oral method or backup contraception for four weeks after starting and after each dose increase.
  • On injectable semaglutide (Ozempic, Wegovy) the dedicated study found no loss of pill exposure; a pharmacist conversation covers vomiting or diarrhea windows under your pill brand's missed-dose rules.
  • Planning pregnancy: semaglutide is stopped at least two months ahead per the label.

← All reviewed pairs for GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)